HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo

Patients whose NSCLC tumors become afatinib resistant presently have few effective therapeutic options to extend their survival. Afatinib resistant NSCLC cells were sensitive to clinically relevant concentrations of the irreversible pan-HER inhibitor neratinib, but not by the first generation ERBB1/...

Descripción completa

Detalles Bibliográficos
Autores principales: Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Avogadri-Connors, Francesca, Cutler, Richard E., Lalani, Alshad S., Dent, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685747/
https://www.ncbi.nlm.nih.gov/pubmed/29163826
http://dx.doi.org/10.18632/oncotarget.21660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685747/
https://www.ncbi.nlm.nih.gov/pubmed/29163826
http://dx.doi.org/10.18632/oncotarget.21660

Ejemplares similares